Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET

Company Participants

Christine Cassiano - Chief Corporate Affair and Brand Strategy Officer
David Chang - President and Chief Executive Officer
Zachary Roberts - EVP of Research and Development and Chief Medical Officer
Geoff Parker - Chief Financial Officer

Conference Call Participants

Michael Yee - Jefferies
Jack Allen - Baird
Biren Amin - Piper Sandler
John Newman - Canaccord Genuity
Luca Issi - RBC Capital
Samantha Semenkow - Citi
Matthew Biegler - Oppenheimer
Brooke Schuster - William Blair
William Pickering - Bernstein
Laura Prendergast - Raymond James

Operator

Hello, and thank you for standing by. Welcome to Allogene Therapeutics' Third Quarter 2024 Conference Call. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions].

I would now like to turn the call over to Christine Cassiano, Chief Corporate Affair and Brand Strategy Officer. Ms. Cassiano, please go ahead.

Christine Cassiano

Thank you, operator, and welcome to all who have joined this call. After the market closed today, Allogene issued a press release that provides a business update and financial results for the third quarter of 2024. This press release and today's webcast are available on our website. Following our prepared remarks, we will host a Q&A session. We recognize that historically questions have been multifaceted, but note that we will endeavor to keep this call to under an hour.

Joining me today are Dr. David Chang, President and Chief Executive Officer; Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer; and Geoff Parker, Chief Financial Officer.

During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, commercial market forecasts, and 2024 financial guidance, among other things.

These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of the potential risks can be found in our press release and latest SEC disclosure documents. You are cautioned not to place undue reliance on these forward-looking statements, and Allogene disclaims any obligation to update these statements.

I'll now turn the call over to David.

David Chang

Thank you, Christine, and welcome to those on the call today.

Today, I'm excited to share our recent progress and upcoming milestones as we continue our mission to redefine cell therapy for both cancer and autoimmune disease. In the third quarter, our groundbreaking achievements include: One, in heme malignancy, we continue to activate sites and advance the pivotal Phase II ALPHA3 trial of cema-cel for large B cell lymphoma. This trial marks a significant step forward as cema-cel could become the first CAR T therapy integrated into the first line treatment.